An increasingly popular antigen in hematology-oncology as well as solid tumor oncology is CD70, with a number of players developing therapies to target it. But Pfizer believes its PF-08046040, acquired through its purchase of Seagen, could target CD70 in a way more amenable to elderly patients.
The drug maker presented Phase I data in a poster on 7 December at the American Society of Hematology annual...